Skip to main
JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals (JAZZ) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 47%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Jazz Pharmaceuticals is a strong player in the biopharmaceutical industry with a diverse portfolio of approved drugs and a promising pipeline of neuro assets. Their recent acquisitions and development of new treatments, coupled with potential for strong international sales, indicate potential for further growth. However, investors should also consider potential risks in the highly regulated and competitive biotechnology sector.

Bears say

Jazz Pharmaceuticals is experiencing strong quarterly revenue growth, indicating that the company is able to execute on its existing commercial business and exceed performance expectations. Risks to the company include potential erosion of its Xyrem franchise due to competition, slower growth on both the top and bottom line, and potential exposure to macro headwinds. The company's recent acquisition of GW Pharmaceuticals provides potential for future revenue growth, but materiality of ESG factors and changes in the market cannot be underestimated.

Jazz Pharmaceuticals (JAZZ) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 47% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Jazz Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Jazz Pharmaceuticals (JAZZ) Forecast

Analysts have given Jazz Pharmaceuticals (JAZZ) a Buy based on their latest research and market trends.

According to 17 analysts, Jazz Pharmaceuticals (JAZZ) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $273.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $273.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Jazz Pharmaceuticals (JAZZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.